Periprocedural antithrombotic therapy during various types of percutaneous cardiovascular interventions

P. Widimský*, V. Kočka, F. Roháč, and P. Osmančík

Cardiocenter, University Hospital Kralovske Vinohrady, Third Faculty of Medicine, Charles University Prague, Srobarova 50, 100 34 Prague 10, Czech Republic

Received 2 November 2015; revised 7 December 2015; accepted 8 December 2015; online publish-ahead-of-print 11 December 2015

Introduction

Percutaneous catheter-based interventions became a critically important part of treatment in modern cardiology, improving quality of life as well as saving many lives. Due to the introduction of foreign materials to the circulation (either temporarily or permanently) and due to a certain damage to the endothelium or endocardium, the risk of thrombotic complications is substantial and thus some degree of antithrombotic therapy is needed during all these procedures. The intensity (dosage, combination, and duration) of periprocedural antithrombotic treatment largely varies based on the type of procedure, clinical setting, and comorbidities. This manuscript summarizes the current therapeutic approach to prevent clotting (and bleeding) during a large spectrum of interventions: acute and elective coronary interventions, acute stroke interventions and elective carotid stenting, electrophysiology procedures, interventions for structural heart disease, and peripheral arterial interventions.

Keywords

Percutaneous interventions • Antithrombotic therapy • Anticoagulants • Antiplatelet drugs • Thrombolytics • Stents • Ablation • Device implantation

Periprocedural oral antiplatelet therapy

An oral loading dose of ASA 150–300 mg (or i.v. 80–150 mg) should be given to all patients. The preferred P2Y12 inhibitors are prasugrel (60 mg p.o. loading dose) or ticagrelor (180 mg p.o. loading dose).4,5 In the STEMI subgroup of the TRITON–TIMI 38 trial, prasugrel was superior to clopidogrel (primary endpoint prasugrel 10.0% vs. clopidogrel 12.4%), without a significant increase in non-CABG-related bleeding (2.4% vs. 2.1%). There was a lower risk of stent thrombosis (1.6% vs. 2.8%), as well as of cardiovascular mortality (1.4% vs. 2.4%) in favour of prasugrel. Prasugrel is
contraindicated in patients with prior stroke or TIA and not recommended for patients aged 75 years or more. In patients with body weight <60 kg, a maintenance dose of 5 mg is recommended.

In the STEMI subgroup of the PLATO trial, ticagrelor was superior to clopidogrel (primary endpoint 9.4% vs. 10.8%) without higher risk of bleeding (TIMI non-CABG major 2.5% vs. 2.2%) but with a trend towards a lower risk of cardiovascular mortality at 1 year (4.7% vs. 5.4%).

In a pooled analysis of 48 599 patients, novel P2Y12 inhibitors prasugrel or ticagrelor have been associated with a mortality benefit and no significant excess of major bleeding among STEMI patients. Importantly, the more potent agents (prasugrel and ticagrelor) should not be used in patients with prior haemorrhagic stroke or with moderate-to-severe liver disease.

When neither of these agents is available (or if they are contraindicated), clopidogrel 600 mg p.o. should be given instead to fulfil the requirement for dual antiplatelet therapy (DAPT).

Intravenous antiplatelet therapy

Trials (mostly using abciximab) performed before the era of thienopyridines pre-loading documented clinical benefits from GPIIb/IIIa inhibitors as adjunct to primary PCI performed with UFH including a significant 1-year survival benefit that was revealed in a meta-analysis of GP IIb/IIIa inhibitors with abciximab. However, the benefits of GPIIb/IIa inhibitors in the era of potent novel P2Y12 inhibitors are questionable and there is a high likelihood of bleeding complications when four antithrombotic agents (aspirin, P2Y12 inhibitors, injectable anticoagulant, and GPIIb/IIa inhibitors) are combined simultaneously.

In the event of angiographic evidence of large thrombus, slow- or no-reflow, and other thrombotic complications, use of GP IIb/IIa inhibitors as bail-out therapy appears reasonable, although this has not been tested in a randomized trial.

The FINESSE study randomized STEMI patients to upstream abciximab at the first medical contact vs. in-cath-lab abciximab and found no significant effect on the primary endpoint (death, recurrent myocardial infarction, and heart failure), but significantly increased bleeding risk after upstream abciximab.

Cangrelor, an intravenous rapidly acting P2Y12 inhibitor (dose 30 μg/kg bolus followed by infusion of 4 μg/kg/min), was compared with a 600-ng loading dose of clopidogrel either before or early after PCI in patients with ACS undergoing PCI in The CHAMPION PLATFORM and PCI studies. A minor benefit from cangrelor was observed, however, it is not known whether this benefit would apply also if cangrelor would be compared with prasugrel or ticagrelor.

Injectable anticoagulants

Heparin

Despite the lack of large randomized trials, unfractionated heparin (UFH) remains the cornerstone of anticoagulation treatment in STEMI patients planned to undergo primary PCI. Several other drugs have been compared with heparin, but none of them was proven to be superior. There is however one critically important issue in heparin treatment: the dose MUST be adapted to the patient body weight: if no GPIIb/IIa inhibitors are planned (what is the current routine practice in most centres), the dose of UFH should be 70–100 units kg⁻¹ (lower dose preferred in elderly patients especially fragile females with low body weight). A frequent mistake in the real life practice is the use of an arbitrary UFH dose (e.g. 5000 or 10 000 units) for all patients, irrespective of body weight. An arbitrary 5000 unit dose will certainly be ineffective for a 95-kg middle-aged smoker and on the other hand arbitrary 10 000 units may be an extremely dangerous overdose (risk of intracranial bleeding) for an elderly 55 kg female.

Bivalirubin

Bivalirubin was assessed in several randomized trials. In the HORIZONS-AMI trial, bivalirudin alone (with bail-out GP IIb/IIa inhibitors in 7.2% of patients) was superior to combined therapy with UFH plus systematic GP IIb/IIa inhibitor (mostly abciximab). However, the net adverse clinical endpoint (9.2% vs. 12.1%) included major bleeding (4.9% vs. 8.3%). Thus, it is not surprising that combination of two potent antithrombotic drugs was more harmful than a single drug. There was no significant difference in the ischaemic endpoints, even there was a higher incidence of stent thrombosis in the bivalirudin group (1.3% vs. 0.3%).

The same problem was in the design of the EUROMAX trial comparing a single drug strategy (pre-hospital bivalirudin) vs. a combination strategy (heparin with optional—69% patients—GPIIb/IIa inhibitors). The primary endpoint (death or non-CABG major bleeding at 30 days) again included bleeding (2.6% vs. 6.0%) and was significantly lower with pre-hospital administration of bivalirudin (5.1% vs. 8.5%). Again, similarly to the HORIZONS-AMI trial, there were no differences in ischaemic endpoints: death (2.9% vs. 3.1%), stent thrombosis (1.6% vs. 0.5%), and re-infarction (1.7% vs. 0.9%).

The HEAT-PCI study compared bivalirudin vs. UFH with similar rates (15%) of GPIIb/IIa inhibitors in both arms. The study better represents contemporary practice (restriction of GP IIb/IIa inhibitors to bail-out situations, the use of novel P2Y12 inhibitors, radial approach and drug-eluting stent, DES, implantation). The primary efficacy endpoint (all-cause mortality, stroke, recurrent infarction, and unplanned target lesion revascularization) was higher in the bivalirudin than in the UFH group (8.7% vs. 5.7%) including an increase in stent thrombosis (3.4% vs. 0.9%), but no significant difference in mortality (5.1% vs. 4.3%). The primary safety outcome (major BARC 3–5 bleeding) was 3.5% in the bivalirudin group vs. 3.1% in the UFH group.

Thus, the entire treatment benefit of bivalirudin demonstrated in HORIZONS-AMI and EUROMAX trials was caused by the study design (low use of GPIIb/IIa inhibitors in the bivalirudin arm) and cannot answer the question whether bivalirudin is superior to heparin or vice versa. The results of HEAT-PCI study suggest, that heparin may be even superior to bivalirudin when the same rate of GPIIb/IIa inhibition is used. A problem with bivalirudin is also that results were better in subject at low risk (no troponin) but not in those with high troponin (high risk); therefore, bivalirudin seems to provide no advantages high-risk patients.

Enoxaparin

Enoxaparin (0.5 mg/kg i.v. bolus followed by subcutaneous treatment, dose adjustment to impaired renal function is essential) was compared with UFH in the ATOLL trial. The primary composite endpoint (30-day death, complication of myocardial infarction, procedural failure, and major bleeding) was not significantly different, but secondary endpoints suggested possible benefit from enoxaparin. In the
angiography in SCAD.20 for systematic clopidogrel pre-loading before diagnostic coronary chronic aspirin and/or clopidogrel therapy, the loading dose before body weight: 70–100 units kg

The total UFH dose should be ALLWAYS calculated per the patient ad hoc

formation, slow flow, and threatened vessel closure).24 be beneficial in ‘bail-out’ situations (intraprocedure thrombus dotal experience, however, suggests that GP IIb/IIIa inhibitors may

IIIa inhibitors after a clopidogrel loading dose of 600 mg.21– 23 Anec-

ment for elective PCI.3 Heparin is usually given in the cath-lab in two separate doses: initial small dose at the beginning of diagnostic angio-

graphic and second dose after the decision for ad hoc PCI is taken. The total UFH dose should be ALWAYS calculated per the patient body weight: 70–100 units kg

The second antiplatelet drug (P2Y12 inhibitor) is usually added in the cath-lab just prior to PCI, i.e. between angiography and PCI.

Elective percutaneous coronary interventions for stable coronary artery disease

Ad hoc percutaneous coronary intervention

Most patients with stable coronary artery disease nowadays undergo elective coronary angiography immediately followed by ad hoc PCI. In such situation, pretreatment with aspirin is widely used (usually due to a known diagnosis of coronary artery disease and not specifically due to the diagnostic angiography) and possibly is appropriate (albeit was never tested in a randomized trial). Anticoagulation with UFH (i.e. bolus of 70– 100 U/kg) remains the standard anticoagulant treat-

ment for elective PCI.2 Heparin is usually given in the cath-lab in two different doses: initial small dose at the beginning of diagnostic angiography and second dose after the decision for ad hoc PCI is taken. The total UFH dose should be calculated per the patient body weight: 70–100 units kg

The second antiplatelet drug (P2Y12 inhibitor) is usually added in the cath-lab just prior to PCI, i.e. between angiography and PCI.

Planned elective percutaneous coronary intervention

Patients with known coronary angiography scheduled for elective PCI should be pretreated with DAPT at least few hours before the procedure and UFH should be used in the way described above as well. In patients not using any chronic antiplatelet therapy, the oral loading dose of ASA should be 150–300 mg (or 80–150 mg i.v.) and clopidogrel loading dose 300–600 mg.17–19 In patients on chronic aspirin and/or clopidogrel therapy, the loading dose before an elective procedure is not needed. There is no evidence of benefit for systematic clopidogrel pre-loading before diagnostic coronary angiography in SCAD.20

Recent trials did not demonstrate additional benefit from GP IIb/ Illa inhibitors after a clopidogrel loading dose of 600 mg.21–23 Anec-
dotal experience, however, suggests that GP IIb/IIa inhibitors may be beneficial in ‘bail-out’ situations (intraprocedure thrombus formation, slow flow, and threatened vessel closure).24

Percutaneous coronary interventions in patients with atrial fibrillation

Approximately 10% of patients undergoing PCI have another indication for long-term oral anticoagulation (OAC)—most frequently concomitant atrial fibrillation. There is an ongoing debate about the optimal antithrombotic medication in these patients theoretically requiring triple therapy: OAC permanently and DAPT for 1 year. In practice, the best approach is individual decision based on the concrete bleeding risk vs. stent thrombosis risk. Patients with increased bleeding risk should receive triple therapy during the first month after stent implantation followed by long-term dual therapy (OAC + clopidogrel or OAC + aspirin). Patients at low-bleeding risk may receive triple therapy up to 6 months, followed by long-
term OAC + aspirin.

Interventions for structural heart disease

Structural heart interventions are a heterogeneous mixture of usually elective procedures ranging from the technically simple and short patent foramen ovale closure to long and complex interven-
tions on mitral valve. Most of structural heart interventions involve rather large devices. These devices are typically metallic (stainless steel and nitinol are the most common); Dacron type polyester fabric to promote tissue growth or pericardial tissue made valve prosthesis are often present.

Intravenous heparin is the dominant periprocedural anticoagulant because of familiarity to all operators, availability of antidote and low cost. Level of anticoagulation can be adjusted according to activated clotting time (ACT). However, the optimal target ACT is mostly not clear. Intriguingly, one single centre study elegantly demonstrated abnormal baseline ACT values prior to transcatheter aortic valve implantation (TAVI) in typical elderly and frail population and heparin dosing adjustment lead to less bleeding.25 Access site bleeding is obviously more common after arterial puncture than venous one; it is clear from TAVI data that arterial bleeding complications lead to a significant increase in early mortality. Many structural interventions involve catheter manipulation of right and left atria (i.e. thin-walled structures) with 1–2% risk of perforation and resulting cardiac tamponade. On the other hand, the longer procedure duration and the slower blood circulation around catheters both increase the risk of thrombus formation with possible embolization leading to disabling stroke or other organ embolization. Reversal of heparin activity with protamine is generally not recommended but can be very useful in case of bleeding. Bivalirudin has been compared with heparin in a randomized BRAVO 3 study of TAVI. There was no reduction in bleeding and heparin remains the standard of periprocedural care.26

Patients on OAC have this therapy interrupted for the procedure to minimize bleeding complications. Bridging with unfractionated or low-molecular heparin should be individualized based on every patient risk of bleeding and thrombosis.27 Suitable timing of OAC re-

start after the procedure is not well defined and is probably best left at discretion of attending physician. The role of new oral anticoagu-
lants (NOACs) for structural heart interventions is not yet defined; dabigatran caused harm in patients with mechanical heart valves28 and ongoing Atlantis study currently evaluates apixaban after TAVI.

Antiplatelet therapy is commonly prescribed just before and con-
tinued after structural heart interventions with the aim to prevent thrombotic complications until endothelization of implanted device is completed. Only aspirin and clopidogrel have been studied in this
Electronic device implantation

As with any small surgery, also implantation of cardiac implantable electronic devices (CIED) is also associated with a risk of bleeding. Hematomas following CIED implantation are quite frequent (2.9–9.5% of the cases). Although bleeding following CIED implantation is typically small and only very rarely life threatening, it prolongs hospitalization, increases the costs and surgical haematoma evacuation is associated with 15 times higher risk of infection.

Unfortunately, many patients indicated for CIED implantation are also indicated for antithrombotic or anticoagulant treatment. Data on contemporary populations from clinical studies and surveys indicate a rate of use of anticoagulant therapy ranging from 15% in patients with pacemakers, to 35% in patients with ICDs, reaching almost 50% in patients with cardiac resynchronization therapy. Moreover, ~50% of these patients have an indication for single or dual antiplatelet treatment. Typical examples are patients with a history of atrial fibrillation (either with slow ventricular response or as a part of sick sinus syndrome) or patients after valve surgery. Moreover, antithrombotic and anticoagulant treatment has changed within last 10 years with new and more potent drugs present on the market, such as prasugrel, ticagrelor or NOAC, and some patients requires a combination of anticoagulant and antiplatelet treatment, which makes the situation even more complicated.

Cardiac implantable electronic devices implantation and anticoagulation

The management of anticoagulation and antiplatelet treatment during CIED implantation has changed substantially within last ten years. According to the ESC guidelines for cardiac pacing from 2007, anticoagulation treatment should have been interrupted 3–8 days pre-operatively and replaced with heparin. This is in complete contradiction with the ESC guidelines from 2013. According to these recent guidelines, the use of heparin bridging to OAC has been shown to increase the risk of bleeding and continuation of warfarin is recommended instead.30–32

The first study reporting the feasibility of implantation with ongoing warfarin was a study by Goldstein et al.31 However, the majority of the 37 patients in this study underwent generator replacement and not leads and pacemaker de novo implantation. Since then a number of observational studies and recent randomized studies have confirmed the superiority of warfarin continuation to bridging to heparin. In the BRUISE CONTROL study,32 i.e. the largest randomized study comparing ongoing warfarin to bridging to heparin strategy, warfarin continuation was associated with significantly

---

**Table 1**

| Procedure | Typical access | Procedure time (min) | Main catheter size (French) | Left atrium manipulation | Access on venous side | Heparin | Guideline or IFU target | ACT (s) | Warfarin new indication (months) | NOAC (months) | References |
|-----------|----------------|----------------------|-----------------------------|--------------------------|----------------------|--------|------------------------|--------|-----------------------------|----------------|------------|
| PTMV      | Venous         | 40–50                | 9–12                        | Yes                      | 3–5                  | Yes    | Frequent               | 300    | None                        | No             | 6–8        |
| PFO closure| Venous         | 10–50                | 7–9                         | Yes                      | Not measured         | Very low | Variable               | 1.6–6  | 0–1                        | 1112           | 9,10       |
| ASD closure| Venous         | 65                   | 7–12                        | Yes                      | 3–5                  | Yes    | Always                 | 200    | No                          | No             | 6 to 24    |
| LAA occlusion| Venous       | 30–60                | 12                          | Yes                      | 3–4                 | Yes    | 200 or 250             | 300    | 250                        | 15–19          | 9,14       |
| TAVI 2× arterial | Venous | 180                  | 60–135                      | Yes                      | 33–47               | Yes    | 250                     | 250    | 75–100                      | 20–22          |            |
| MitraClip | Venous         | 100                  | 24                          | Yes                      | 34–48               | Yes    | 250                     | 300    | 0.7–2.1                    | To be tested   |            |

PTMV, percutaneous transvenous mitral valvuloplasty; PFO, patent foramen ovale; ASD, atrial septal defect; LAA, left atrial appendage; TAVI, transcatheter aortic valve implantation; IFU, instructions for use; ACT, activated clotting time; NOAC, new oral anticoagulant.
lower risk of bleeding (RR 0.16, 95% CI 0.08–0.32) and no difference in the risk of thromboembolic events. Recently, observational and small randomized trials have shown similar incidences of bleeding complications during CIED implantation with uninterrupted novel anticoagulants (NOACs) or warfarin.33

In patients with moderate or even high risk (such as in patients with artificial valves, recent pulmonary embolisms or in patients with history of AF and higher CHADS2VASc scores), the implantation of CIED should be done while on p.o. anticoagulation, with careful haemostasis during surgery.

Cardiac implantable electronic devices and antiplatelet treatment

Compared with untreated patients, aspirin carries a two-fold risk of bleeding and DAPT (aspirin plus thienopyridine) carries a four-fold or according some authors even a six-fold risk of bleeding during the peri-operative period. This risk was reduced by withholding clopidogrel 4–7 days before implantation. In most cases, dual antiplatelet medications can safely be discontinued, for a period of 5–7 days.

Ablation of cardiac arrhythmias

Ablation and anticoagulant treatment

Left-sided ablations present a high risk of periprocedural thromboembolic events due to (i) the disease itself (typically atrial fibrillation), (ii) the differences in the clot formation in the right- and left-sided atria and ventricles, and (iii) the difference in the clinical manifestation in case of the embolization of right- and left-sided cardiac chambers. While thrombi from the right-sided cardiac chambers remain mostly asymptomatic, even small thrombus from the left atrium can lead to stroke with severe neurologic disability.

All left-sided ablations were previously performed on heparin and the same was true of CIED implantation, patients were bridged to heparin from p.o. warfarin. The development of ongoing warfarin during ablation has followed a similar path to its use with CIED implantation. Recently, according to non-randomized observational studies and randomized trials, ongoing uninterrupted warfarin has been shown to be safe and associated with lower rates of bleeding events, and lower rate of thromboembolic events compared with bridging to heparin.34 In these trials, target international normalized ratio (INR) before and during ablation was 2.0–3.0 and was checked one day before the procedure. In patients with uninterrupted warfarin, periprocedurally heparin was given to all of them with similar target ACT values. Not surprisingly, patients on uninterrupted warfarin had lower stroke events compared with bridging strategy (OR 0.17, 95% CI 0.08–0.35) according to the meta-analysis of 12 observational and randomized trials comparing this two strategies.35

Surprisingly, the rates of major (OR 0.72, 95% CI 0.54–0.95) and minor bleedings (OR 0.33, 95% CI 0.21–0.52) were also reduced in the uninterrupted warfarin strategy. It has become clear that hold- minor bleedings (OR 0.33, 95% CI 0.21–0.52) were also reduced in the uninterrupted warfarin strategy. It has become clear that hold-

Ablation and antiplatelet treatment

There is only a few reports regarding the risk and complications of catheter ablation if performed with concomitant dual antiplatelet and anticoagulant treatment. However, available reports indicate higher incidence of bleeding and vascular complications in ablation performed with clopidogrel.36 Catheter ablation present mostly elective procedure, and so discontinuation of clopidogrel or other thienopyridines is recommended.

Catheter-based interventions for acute ischaemic stroke

There is lack of scientific evidence and complete absence of official guidelines recommending any specific protocol for periprocedural antithrombotic treatment during acute stroke interventions. Possibly, the most comprehensive document on this subject—the American guidelines for the management of acute stroke39,40—describe the reperfusion strategies and the use (or rather no use) of anticoagulant and antiplatelet agents as the potential primary therapy for stroke (when no reperfusion strategies are used), but not as periprocedural therapy during catheter-based thrombectomy (CBT).

Thrombolysis

These 2013 guidelines only describe thrombolysis use in acute ischaemic stroke. Intraavenous thrombolysis is indicated for all eligible (per guidelines) stroke patients irrespective whether subsequent endovascular intervention is planned. The 2015 update40 and the Canadian guidelines41 further specify that endovascular intervention is indicated for all eligible acute ischaemic stroke patients including patients with contraindications to thrombolysis. When i.v. thrombolysis is used, the endovascular intervention should commence immediately, without waiting for the effect of thrombolysis. Nowadays, when stent-retrievers are much faster and much more effective, i.e. use of rtPA is reserved only for patients with more distal occlusions, not accessible with stent-retrievers and as a primary therapy is abandoned. Table 2 presents the current indications for acute stroke interventions according to the use of bridging thrombolysis.

Anticoagulants

As mentioned above, no information is given in these three guideline documents about the use of anticoagulants during CBT in patients with contraindications for thrombolysis. In general, urgent anticoagulation with the goal of preventing early recurrent stroke or improving stroke outcomes or for the management of non-cerebrovascular conditions is not recommended due to the risk of serious intracranial haemorrhage (IIIA recommendation). Anticoagulant therapy within 24 h after rtPA is not recommended (IIIB).

Antiplatelet agents

Similarly, no recommendation is given for periprocedural use of antiplatelet agents. Acetylsalicylic acid is not recommended as a substitute for other acute interventions (IIIB), ASA is not recommended.
Intravenous thrombolysis was used in 60% of patients prior to the procedure. Periprocedural antithrombotic treatment usually included aspirin, usually 300 mg given routinely. If no hemorrhage was present, aspirin 300 mg/day should be continued. Patients treated by direct CBT in a Turkish study received 100 mg ASA before CBT in the emergency department. During the recanalization attempt was unsuccessful. When stent placement was needed, antiplatelet management consisted of 500 mg of aspirin given routinely. No further antiplatelet or heparin was administered. A flushing solution on the sideport of the sheath was used routinely by 50% of radiologists for CAS. Periprocedural UHF is commonly used. Unfractionated heparin was used by almost all radiologists as a bolus (5000 IU was the most used dosage, additional smaller bolus usually repeated after 1 h in longer procedures).53

### Table 2 Indications for acute stroke interventions with and without bridging thrombolysis

|                        | Facilitated intervention (bridging thrombolysis)* | Direct intervention (thrombolysis not used) |
|------------------------|--------------------------------------------------|---------------------------------------------|
| Moderate or severe stroke | NIHSS ≥ 6 0–4.5 h                               | NIHSS ≥ 6 0–6 h (6–12 h in selected patients with significant penumbra) |
| Stroke onset—treatment delay a | Bridging thrombolysis not possible              | Remains the only option for reperfusion  ≥ 6 |
| Contraindications for the use of thrombolitics Native CT (ASPECTS score) | ICA, MCA-M1, BA, or VA occlusion | ICA, MCA-M1, BA, or VA occlusion |

NIHSS, National Institutes of Health Stroke Score; CT-A, computed tomography angiogram; MR-A, magnetic resonance angiogram; ICA = internal carotid artery; MCA-M1, M1 segment of the middle cerebral artery; BA, basilar artery; VA, vertebral artery.

*When i.v. t-PA is used, patient should proceed immediately to interventional lab (waiting for the effect of thrombolysis is not anymore acceptable in 2015!).

**Start of CT scan— groin puncture time (including e.v. thrombolysis) should be < 60 min in 90% of patients!**

When native CT scan shows the hyperdense MCA sign, no angiography is necessary, patient should proceed directly to the interventional lab.

as adjunctive therapy within 24 h of i.v. rtPA (IIIc). Oral ASA should be initiated within 24–48 h after stroke onset (IA recommendation). The usefulness of clopidogrel in acute ischaemic stroke is not well established and further research is required (IIbC). Intravenous GPIIb/IIa inhibitors are not recommended (IIIB).

Similar to AHA/ASA guidelines, no information about periprocedural antiocoagulation or antiplatelet treatment is provided in the important multisociety consensus paper on catheter-based interventions in acute stroke.42

### Periprocedural therapy in published trials and registries

Most published trials or registries do not mention periprocedural antithrombotic therapy at all.43–45 A small single centre registry of 23 consecutive cases of emergency carotid stenting followed by mechanical thrombectomy found successful carotid stenting in all cases, and establishment of TICI flow 2a/2b/3 in 91%. Symptomatic intracranial haemorrhage occurred in 5/23 patients (22%). Of 13 patients receiving an intravenous loading dose of abciximab during the procedure, 4/13 had SICH (31%) compared with 1/10 (10%) of those who did not. Of seven patients who received intravenous tissue plasminogen activator prior to the procedure, none had SICH. 90-day mortality was 9/23 (39%). All patients who had SICH were above the median age.46 In the TREVO study, it was recommended that administration of anticoagulants and antiplatelets be suspended for 24 h post-thrombectomy in patients who were not in direct need of these agents. Exclusion criteria: Heparin use within previous 48 h with aPTT > 2 times normal was even an exclusion criterion. Intravenous thrombolysis was used in 60% of patients prior to the endovascular procedure. Periprocedural antithrombotic treatment included i.a. rtPA in 10% and GP IIb/IIIa inhibitors in 5%.47 One study48 used neither i.v. heparin nor intra-arterial fibrinolytics at any time during the mechanical thrombectomy procedure, even if the recanalization attempt was unsuccessful. When stent placement was needed, antiplatelet management consisted of 500 mg of aspirin i.v. during the procedure, and double antiplatelet was discussed after the 24-h CT control in view of any serious haemorrhagic complications. Patients treated by direct CBT in a Turkish study49 received 100 mg ASA before CBT in the emergency department. During interventional stroke procedure, 2000 units of bolus heparin were given routinely. No further antiplatelet or heparin was administered within 24 h of procedure. A CT or MRI was performed 24 h after the procedure. If no haemorrhage was present, aspirin 300 mg/day was given.

### Elective carotid stenting

The optimal anticoagulation regimen for carotid artery stenting (CAS) remains unknown.50 Periprocedural UHF is commonly used. Dual antiplatelet therapy with aspirin and clopidogrel is recommended. Two small, randomized trials comparing aspirin alone with double antiplatelet therapy for CAS were terminated prematurely due to high rates of stent thrombosis and neurological events in the aspirin-alone group.51,52 In patients with proven intolerance to DAPT, CEA should be preferred to CAS. Newer antiplatelet agents such as prasugrel or ticagrelor have not yet been adequately tested in CAS.

A recent survey among the Dutch interventional radiologists showed that almost all continue acetyl salicylic acid till the time of percutaneous interventions. Clopidogrel is stopped in 40% peripheral interventions, but not before CAS. A flushing solution on the sideport of the sheath was used routinely by 50% of radiologists during CAS, but only a minority of them (28%) used a heparinized flushing solution. Unfractionated heparin was used by almost all radiologists as a bolus (5000 IU was the most used dosage, additional smaller bolus usually repeated after 1 h in longer procedures).53

### Interventions for peripheral arterial disease

Antiplatelet therapy with aspirin (or clopidogrel) is recommended to reduce overall cardiovascular risk in chronic symptomatic lower extremity artery disease (LEAD) patients.50,54 Data on periprocedural antithrombotic therapy in LEAD interventions are sparse. Most published data deal with pharmacological treatment following revascularization procedures, but not during such procedures. Recommendations are based on expert consensus only. Acetylsalicylic...
Table 3  Summary on the periprocedural use of antithrombotic drugs

| Antithrombotic Therapy | PCI for AMI | Elective PCI | Structural interventions | Electronic device implantation | Arrhythmias ablation | Acute stroke (thrombectomy) | Elective carotid stenting | Peripheral arterial interventions |
|------------------------|-------------|--------------|------------------------|-------------------------------|---------------------|-----------------------------|--------------------------|----------------------------------|
| Thrombolytics          | NO (exception: pre-hospital thrombolysis in patients with very long delays to PCI) | NO | NO | NO | NO | YES as bridging therapy in eligible patients | NO | NO for most cases. YES (local thrombolysis) in selected cases |
| Injectable anticoagulants | YES (heparin or enoxaparin or bivalirudin, dosage of anticoagulant must be adopted to body weight) | YES (heparin or enoxaparin, dosage of anticoagulant must be adopted to body weight) | YES (heparin, dosage adopted to body weight and to ACT!) | NO | YES for patients who are not on chronic OAC. NO for temporary replacement of OAC | NO for patients who received bridging rTPA. YES (low dose heparin) for patients treated with direct thrombectomy without rTPA | YES | YES |
| Oral anticoagulants    | NO if patient with AMI is on chronic OAC, no or lower dose heparin should be used | NO If chronic use, OAC should be interrupted before PCI | NO If chronic use, OAC should be interrupted before PCI | NO If patient is on chronic OAC, therapy should continue (careful timing of implantation with respect to OAC dosage) | YES for patients who are on chronic OAC—they should not interrupt treatment | NO if patient with acute stroke is on chronic OAC, no anticoagulants should be added during mechanical intervention | NO | NO |
| Acetylsalicylic acid   | YES | YES | YES | NO (If chronic use should be discontinued 5–7 days before implantation) | NO (If chronic use should be discontinued 5–7 days before implantation) | NO (Exception: YES just prior to carotid stenting in the acute phase of stroke) | YES | YES |
| P2Y12 inhibitors       | YES | YES | YES | NO (If chronic use, should be discontinued 5–7 days before implantation) | NO (If chronic use, should be discontinued 5–7 days before implantation) | NO (If carotid stenting was part of the acute procedure, P2Y12 inhibitors should be initiated after control CT scan post-thrombectomy procedure) | YES | YES if stent implantation |
| GPIIb/IIIa inhibitors  | Routine upfront use not indicated. Selective (bail-out) use in cath-lab only | NO | NO | NO | NO | NO | NO | NO |

PCI, percutaneous coronary intervention; AMI, acute myocardial infarction; GP, glycoprotein; OAC, oral anticoagulants.
critical limb ischaemia, the extent of stenting, the use of covered disease, the quality of the inflow and the outflow, the presence of Individualized therapy taking into account the diffuseness of the data from coronary interventions (PCI) and prolong DAPT therapy. In LEAD interventions, some centres adjust their protocols adapting to this initial survey of opinions and practice.59

When arterial access is obtained to allow time for optimal anticoagulation and endovascular aneurysm repair work. The bolus should be given after ward therapeutic procedures and 5000 IU for complex, crural, and that 3000 IU bolus is considered the standard dose for straightfor-ward balloon PTA is not superior over ASA, but has higher bleeding risk.50 Due to the lacking data regarding antithrombotic treatment in LEAD interventions, some centres adjust their protocols adapting data from coronary interventions (PCI) and prolong DAPT therapy. Individualized therapy taking into account the diffuseness of the disease, the quality of the inflow and the outflow, the presence of critical limb ischaemia, the extent of stenting, the use of covered stents, and the stent fracture risk is reasonable.58

The survey of the British Society of Interventional Radiology was summarized with the following recommendation: heparinized saline should be used at a recognized standard concentration of 1000 IU/l as a flushing concentration in all arterial vascular interventions and that 3000 IU bolus is considered the standard dose for straightfor-ward therapeutic procedures and 5000 IU for complex, crural, and endovascular aneurysm repair work. The bolus should be given after arterial access is obtained to allow time for optimal anticoagulation to be achieved by the time of active intervention and stenting. Further research into clotting abnormalities following such intervention-al procedures would be an interesting quantifiable follow-up to this initial survey of opinions and practice.59

Antithrombotic strategies in cardiac patients undergoing non-cardiac surgery

Aspirin and P2Y12 inhibitors
The timing of non-cardiac surgery should always be weighted individually based on the nature of surgical illness vs. the cardiac illness. Early (4 weeks) after stent implantation DAPT should be continued in all patients unless the risk of life-threatening surgical bleeding is unacceptably high. Continuation of aspirin may be considered in the peri-operative period. Stopping aspirin therapy should be considered if haemostasis may be difficult to control during surgery. In patients treated with P2Y12 inhibitors, who need to undergo surgery, postponing surgery for 5–7 days after P2Y12 inhibitor cessation should be considered unless the patient is at high risk of an ischaemic event.60

Anticoagulants
The bleeding risk should be individually weighed against the benefit of anticoagulants. Patients treated with vitamin K antagonists (VKAs) should have the INR < 1.5 to undergo surgery safely. In patients with a high risk of thrombo-embolism (atrial fibrillation with a CHA2DS2-VASc score ≥ 4 or mechanical prosthetic valves or recent venous thrombo-embolism) discontinuation of VKAs is hazardous and these patients will need bridging therapy with a therapeutic-dose of LMWH. Vitamin K antagonist treatment should be stopped 3–5 days before surgery, with daily INR measurements, until ≤ 1.5 is reached, and LMWH should be started 1 day after discontinuation of VKA. Low-molecular-weight heparin is resumed at the pre-procedural dose 1–2 days after surgery, depending on the patient’s haemostatic status, but at least 12 h after the procedure. Vitamin K antagonists should be resumed on Day 1 or 2 after surgery—depending on adequate haemostasis—with the pre-operative maintenance dose plus a boosting dose of 50% for two consecutive days. Low-molecular-weight heparin should be continued until the INR returns to therapeutic levels.

Direct oral anticoagulants
Direct oral anticoagulants (dabigatran, rivaroxaban, apixaban, or edoxaban) have a well-defined ‘on’ and ‘off’ action, ‘bridging’ to surgery is in most cases unnecessary, due to their short biological half-lives.

Summary
The periprocedural antithrombotic strategies vary between different types of percutaneous cardiovascular interventions. Heparin remains the key drug for most of these interventions. Oral antiplatelet drugs are essential when stents are implanted. Oral anticoagulants used chronically are not interrupted during most interventions in electrophysiology. Thrombolysis remains important part of acute stroke treatment. Overview on the use of antithrombotic drugs in different settings is summarized in Table 3.

Funding
The authors receive support from the Charles University Prague, Third Faculty of Medicine, research project P35. Funding to pay the Open Access publication charges for this article was provided by the Charles University Prague, project P35.

Conflict of interest: none declared.

References
1. Widimsky P, Rokyta R, Stasek J, Belohlawek J, Cervinka P, Kala P, on behalf of the Czech Society of Cardiology. Acute coronary syndromes with ongoing myocardial ischemia (ACS with OMI) versus acute coronary syndromes without ongoing ischemia (ACS without OMI). The new classification of acute coronary syndromes should replace old classification based on ST segment elevation presence or absence—Expert consensus statement of the Czech Society of Cardiology. Car Vasc 2013;55:225–227.
2. Steg PG, James SK, Atar D, Badano LP, Blömstrom-Lundqvist C, Borger MA, DiMario C, Dickstein K, Ducrocq G, Fernandez-Avilés F, Gershlick AH, Giannuzzi P, Halvorsen S, Huber K, Juni P, Kastrati A, Knuuti J, Lenzen MJ, Mahaffey KW, Valgimigli M, van ’t Hof A, Widimsky P, Zahger D. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012;33:2569–2619.
3. Windoeker S, Kohl P, Alfonso F, Collet JP, Cremer J, Falk V, Filippatos G, Hamm C, Head Sj, Juni P, Kappetein AP, Kastrati A, Knuuti J, Landmesser U, Laufer G,
Neumann FJ, Richter DJ, Schuette P, Sousa U, M. Stefanini GG, Taggart DP, Terracina L, Valgimigi M, Wijns W, Witkowska A. 2014 ESC/AACCTC Guidelines on myocardial revascularisation: The Task Force on MyocardialRevascularisation of the European Society of Cardiology (ESC) and the European Association forCardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI).

Eur Heart J. 2013;34(2):138–219.

Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horowitz J, Husted S, James K, Maggioni A, Colombo A, von Mangoldt E, Storey RF, Harrington RA, Frey A, Thorsen M. Ticagrelor vs. clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045–1057.

Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzzo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerasooriya G, Gimeno MT. Prasugrel vs. clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357:2001–2015.

Montalescot G, Wiviott SD, Braunwald E, Murphy SA, Gibson CM, McCabe CH, Antman EM, TRITON-TIMI 38 investigators. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): a double-blind, randomised controlled trial. Lancet. 2009;373:723–731.

Steğ PG, James S, Harrington RA, Ardissino D, Becker RC, Cannon CP, Emanuelsson H, Finkelstein A, Husted S, Katus H, Kilhamn J, Olofsson S, Storey RF, Weaver WD, Wallentin L. For the PLATO Study Group. Ticagrelor vs. clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: a platelet inhibition and patient outcomes (PLATO) trial subgroup analysis. Circulation. 2010;122:2131–2141.

Bellemain-Appaix A, Brieger D, Begaï F, Silvain J, Pena A, Cayla G, Barthélémy O, Collot JP, Montalescot G. New P2Y12 inhibitors vs. clopidogrel in percutaneous coronary intervention: a meta-analysis. J Am Coll Cardiol. 2010;56:1542–1551.

Mehta S, Tanguay JF, Eikelboom JW, Teinemaa J, Granger CB, Pocock SJ, Fox KA. Efficacy and safety of ticagrelor versus clopidogrel in patients with acute coronary syndromes treated with percutaneous coronary intervention: a systematic review and meta-analysis. Am Heart J. 2012;163:835.e1–e7.

Kastrati A, Mehlih H, Schuhlen H, Dirschinger J, Dotzer F, ten Berg JM, Meijer F, Buellesfeld L, Holzer C, Gohler P, Schombig I, Intracoronary: A Randomized Trial. JAMA. 2013;309:2507–2516.

Valgimigi M, Percoco G, Barbieri D, Ferrari F, Guagliumi G, Parodi P, Pagnini G, Soukhovomskova O, Ferrari R. The additive value of tirofiban administered with the high-dose bolus in the prevention of ischemic complications during high-risk coronary angioplasty: the ADVANCE Trial. J Am Coll Cardiol. 2004;44:14–19.

Biondi-Zoccai G, Valgimigi M, Margheri M, Mauri A, Lattuada A, Cesare S, Stabile A, Petronio AS, Benetti G, Bolognese L, Bellone P, Sarcella G, Contarini M, Sheiban I, Marra S, Picicione F, Romeo P, Colombo A, Sangiorgi A. Assessing the role of epifibatide in patients with diffuse coronary disease undergoing drug-eluting stenting: the intregilin plus stenting to avoid myocardial necrosis trial. Am Heart J. 2012;163:2705–2713.

Wijns W, Kolh P, Danchin N, Di Mario C, Falk V, Folliguet T, Garg S, Huber K, James K, Knuts J, Lopez-Sendon J, Marco J, Menicanti L, Otjooji O, Pepioli M, Pirlet C, Pomar J, Restanti N, Ribichini F, Schalij M, Sergeant P, Serruys PW, Silber S, Sousa U, Taggart D, Vahanian A, Auricchio A, Bax J, Cecconi C, De Filippi V, Gianfrancesco C, Hobbs F, Kearney M, McDonagh T, Popescu BA, Reiner Z, Sechtem U, Sirtes P, Stankiewicz M, Verheugt F, Yacoub M, von Segesser L, Agewall S, Aladavishili A, Alexopoulos D, Antunes M, Atalar E, Breit de la Riviere A, Danogava A, Ela J, Fajadet J, Ferrera R, Garot J, Halcox J, Hasin Y, Janssens S, Kervinen K, Lauf G, Legrand V, Nashek SA, Neumann FJ, Nikhavanopoulos P, Noc M, Piek J, Pirk J, Rosenbaum Y, Sabate M, Stark R, Thielmann M, Wheatley DJ, Windesecker S, Zembal M. Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2010;31:2501–2555.

Berneli C, Chieffo A, Montorfano M, Plasino F, Giustino G, Buchan GL, Chan J, Costopoulos C, Labat A, Figini F, De Meo E, Giannini F, Covello RD, Gerli C, Franco A, Aglici A, Spagnolo P, Cioni M, Alfieri O, Camici P, Colombo A. Usefulness of baseline activated clotting time-guided heparin administration in reducing bleeding events during transfemoral transcatheater aortic valve implantation. JACC Cardiovasc Interv. 2014;7:1401–1411.

Dangas GD, Lefevre T, Kupp C, Tchettere D, Schafer U, Dumont teil N, Webb JG, Colombo A, Windesecker S, Ten Berg JM, Hildick-Smith D, Mehran R, Boekstegers P, Linke A, Tron C, Van Belle E, Asgar AW, Fak A, Jeger R, Sarcella G, Hink HU, Huasser O, Grube E, Deligrisir EN, Lechthaler I, Bernstam D, Winggard P, Anthopoulos P, Heegensberg C, Investigators B. Bivalirudin versus hypnotic anticoagulation in transcatheater aortic valve replacement. A randomized Phase 3 trial. J Am Coll Cardiol. 2015;65:1003–1003.

Guyatt GH, Alda EA, Crowther M, Schunemann HJ, Gutterman DD, Zelman Lewis S, American College of Chest P. Introduction to the ninth edition: antithrombotic therapy and prevention of thrombosis, 9th ed American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:9 (Suppl):485–525.

Eikelboom JW, Connolly SJ, Brueckmann M, Granger CB, Kappetein AP, Mack MJ, Blazchford JD, Devanny K, Friedman J, Grueter H, Harper K, Rieder Y, Lobmeyer MB, Maas H, Voigt JL, Simoons ML, van de Weel F, Investigators R, Aspirin plus warfarin in patients with mechanical heart valves. N Engl J Med. 2013;369:1206–1214.

Sterling LH, Windle SB, Falcon KB, Eisenberg MJ, Pharmacological management strategies for stroke prevention following transcatheater aortic valve replacement: a systematic review. Int J Cardiol. 2015;191:303–317.

Zacz M, Marcucio R, Pappas M, Contarini M, Nef H, Kolh P, Pagnini P, Pignoli P, Di Corte A, Bongomgi MG, Casillo G. Management of antithrombotic therapy in patients undergoing electrophysiological device surgery. Europace. 2015;17:840–854.
Goldstein DJ, Losquado WP, Spotnitz HM. Outpatient pacemaker procedures in orally anticoagulated patients. Pacing Clin Electrophysiol. 1998;21:1730–1734.

Birnie DH, Healey JS, Wells GA, Verma A, Tang AS, Krahn AD, Simpson CS, Ayala-Paredes F, Couto B, Leira TL, Essebag V. BRUISE CONTROL Investigators. Pacemaker or defibrillator surgery without interruption of anticoagulation. N Engl J Med. 2013;368:2084–2093.

Jennings JM, Robichaux R, McElherty HT, Plum BJ, Gunter A, Doppalapudi H, Osario J, Yamada T, Kay GN. Cardiovascular implantable electronic device circuitry with uninterrupted dbigabran: comparison to interrupted warfarin. J Cardiovasc Electrophysiol. 2013;24:1115–1129.

Di Biase L, Burkhardt JD, Santangeli P, Mohanty P, Sanchez JE, Horton R, Birnie DH, Healey JS, Wells GA, Vermar A, Tang AS, Krahn AD, Simpson CS, et al. Bridging in ablation of atrial fibrillation. J Cardiovasc Electrophysiol. 2013;24:1059–1066.

Nairoz R, Sardar P, Payne J, Aronow WS, Padyuk H. Meta-analysis of major bleeding with uninterrupted warfarin compared to interrupted warfarin and heparin bridging in ablation of atrial fibrillation. Int J Cardiol. 2015;187:426–429.

Cappato R, Marchlinski FE, Hohnloser SH, Naccarelli GV, Xiang J, Wilber DJ, Ma CS, Hess S, Wells DS, Jung A, Vigen J, Hijji BJ, Balasubramaniam R, De Chillou C, Davies DW, Fields LE, Natale A, VENTURE-AF Investigators. Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation. Eur Heart J. 2015;36:1805–1811.

Lu D, Zhang Q, Xiong Y, Wang S. Bleeding risks with novel oral anticoagulants during catheter ablation of atrial fibrillation: a systematic review and network meta-analysis. J Interp Card Electrophysiol. 2015;44:105–111.

Baman TS, Jongnarangsin K, Chugh A, Suwanagool A, Guiot A, Madenci A, Walsh S, Klig J, Gupta SK, Latchamsetty R, Bagwe S, Myles JD, Crawford T, Good E, Bogun F, Pelosi F Jr, Morady F. Oral H. Prevalence and predictors of complications of radiofrequency catheter ablation for atrial fibrillation. J Cardiovasc Electrophysiol. 2011;22:626–631.

Jauch EC, Saver JL, Adams HP, Bruno A, Connors JJ, Demaerschalk BM, Khatri P, Pelosi F Jr, Morady F, Oral H. Prevalence and predictors of complications of radiofrequency catheter ablation for atrial fibrillation. J Cardiovasc Electrophysiol. 2011;22:626–631.

Powars DW, Derdeyn CP, Biller J, Coffey CS, Hoh BL, Jauch EC, Johnston KC, Johnston SC, Khalesi AA, Kidwell CS, Meschia JF, Ovbiagebe B, Yavagal DR, American Heart Association Stroke Stroke. 2013;4:870–947.

Sacks D, Black CM, Cognard C, Connors JJ, III, Frei D, Gupta R, Jovin TG, Kluck B, Meyers PM, Murphy KJ, Ramee S, Rufenacht DA, Bernadette Stallmeyer MJ, Vorwerk D, American Society of Neuroradiology, Canadian Interventional Radiology Association, Cardiovascular and Interventional Radiological Society of Europe, Society for Cardiovascular Angiography and Interventions, European Society of Minimally Invasive Neurological Therapy, Society of Vascular and Interventional Neurology. Multisociety consensus quality improvement guidelines for intraarterial catheter-directed treatment of acute ischemic stroke. J Neurointerv Surg. 2015;7:259–271.

Duda SH, Bosiers M, Lammer J, Scheinert D, Zeller T, Tielbeek A, Anderson J, Hanna EB. Dual antiplatelet therapy in peripheral arterial disease and after peripheral percutaneous revascularization. J Vasc Interv Radiol. 2013;24:152–163.

Gratz PP, Jung S, Schrott G, Gralla J, Schreuder TH, Heijboer RJ, Keizer K, Tielbeek AV, den Hertog HM, Gericts DG, van den Berg-Vos RM, Karas GB, Steyerberg EW, Flach HZ, Marquering HA, Sprengers ME, Jenniskens SF, Beenen LF, van den Berg R, Koudstaal PJ, van Zwan WH, Roos YB, van der Lugt A, van Oostenbrugg RJ, Majoie CB, Dippel DW, MR CLEAN Investigators. A randomized trial of intraarterial treatment for acute ischemic stroke. N Engl J Med. 2015;372:11–20.

Hughes W, Hoit D, Doss VT, Eljovcic F, de Rey, D, Doyler G, Turk AS, Chaudry I, Turner R, Mocco J, Morone P, Fiorella D, Siddiqui A, Mokin M, Arthur AS. Distal aspiration with retrieved stent assisted thrombectomy for the treatment of acute ischemic stroke. J Neurosurg. 2015;7:90–94.

Heck DV, Brown MD. Carotid stenting and intracranial thrombectomy for treatment of acute stroke due to tandem occlusions with aggressive antiplatelet therapy may be associated with a high incidence of intracranial hemorrhage. J Neurosurg. 2015;7:170–175.

Jansen O, Macho JM, Killer-Oberpfalzer M, Liebskinder D, Wahlgren N. TREVO Study Group. Neurothrombectomy for the treatment of acute ischemic stroke: results from the TREVO study. Cerebrovasc Dis. 2013;36:218–223.

Gisacu G, Lobotesis K, Machi P, Maldonado I, Vendrell JF, Riquelme C, Eker O, Mercier G, Mouriard I, Arquian C, Bonafe A, Costatall V. Stent retrievers in acute ischemic stroke: complications and failures during the perioperative period. Am J Neuroradiol. 2015;36:725–731.

Ozdemir O, Giray S, Arlier Z, Funda Ba D, Iancu Y, Colak E. Predictors of a good outcome after endovascular stroke treatment with stent retrievers. Sci World J. 2015;2015:437266. doi: 10.1155/2015/437266.

Tendera M, Aboyans V, Bartelmink LM, Baumgartner I, Clément D, Collet JP, Cremonesi A, De Carlo M, Erbel R, Fowkes FG, Heras M, Kowatiru S, Minar E, Ostergren J, Poldermans D, Rambau V, Rolfi M, Röther J, Sievert H, van Sambeek M, Zeller T, ESC Committee for Practice Guidelines. ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherothrombotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: The Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC), endorsed by the European Stroke Organisation. Eur Heart J. 2011;32:2851–2906.

McKevitt PM, Randall MS, Cleveland TJ, Gaves PA, Tan KT, Venables GS. The benefits of combined endovascular and medical treatment in carotid artery stenting. Eur J Vasc Endovasc Surg. 2005;32:522–527.

Dalalas I, Nano G, Bianchi P, Stegger S, Malarca G, Tedulà DG. Dual antiplatelet regime versus acetylic-acid for carotid artery stenting. Cardiovasc Intervent Radiol. 2006;29:519–521.

Wiersma AP, Vos FA, Bruijnincx CM, van Delden OM, Reijnin JP, Vahl A, Zeebregts CjJ, Moll FL. Periprocedural prophylactic antithrombotic strategies in interventional radiology: current practice in the Netherlands and comparison with the United Kingdom. Cardiovasc Intervent Radiol. 2013;36:1477–1492.

Rooke TW, Tirsch AT, Misra S, Sidawy AN, Beckman JA, Findles L, Gollanian J, Gornik HJ, Hall MR, Moneta GL, Olin JW, Stanley JC, White CJ, White JV, Zierler RE, American College of Cardiology Foundation Task Force, American Heart Association Task Force. Management of patients with peripheral artery disease: an update of 2005 and 2011 ACCF/AHA Guideline Recommendations: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;61:1555–1570.

Adam DJ, Beard JD, Cleveland T, Bell JL, Bradbury AW, Forbes JF. BASIL Trial Participants. Bypass versus angioplasty in severe ischaemia of the leg (BASIL): multicentre, randomised controlled trial. Lancet 2005;365:1925–1934.

Moukarbel GV, Burket PW. Paclitaxel-eluting stents for the treatment of femoropopliteal arterial stenoses: focus on the ZilverPTX drug-eluting peripheral stent. Expert Rev Med Devices. 2015;12:157–162.

Duda SH, Bosiers M, Lammer J, Scheinert D, Zeller T, Tielbeek A, Anderson J, Wiersinger B, Tepe G, Lansky A, Mulde C, Tieleman H, Bierg JP. Sirolimus-eluting versus bare nitinol stent for obstructive superficial femoral artery disease: the SIRCOCCO II trial. J Vasc Interv Radiol. 2006;17:331–338.

Hanna EB. Dual antiplatelet therapy in peripheral arterial disease and after peripher- al punctureaneous revascularization. J Invasive Cardiol. 2012;24:679–684.

Durrant AC, Watts C. Current trends in heparin use during arterial vascular inter- ventional radiology. Cardiovasc Intervent Radiol. 2012;35:1308–1314.

Kristensen SD, Knudt J, Saraste A, Anker S, Batker HE, Hert SD, Ford I, Gorcsan J, van Hees J, Gorenek B, Heyndrickx GR, Hoefert A, Huber K, Kung B, Kjeldsen KS, Longrois D, Lüscher TF, Stanley JC, White CJ, White JV, Zierler RE, American College of Cardiology Foundation Task Force, American Heart Association Task Force. Management of patients with peripheral artery disease: a compilation of 2005 and 2011 ACC/AHA Guideline Recommendations. J Am Coll Cardiol. 2014;63:2383–2431.